GNH USA

Europe — EMA

Mitoxan (Mitoxantrone)

GNH USA supplies Mitoxan (Mitoxantrone), a anthracenedone for acute myeloid leukemia, metastatic breast cancer, prostate cancer and non‑Hodgkin lymphoma.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxan, is an anthracenedone presented as an intravenous injection for use in adult patients with certain hematologic and solid malignancies. It is employed in the treatment of acute myeloid leukemia, metastatic breast cancer, prostate cancer and non‑Hodgkin lymphoma.

GNH USA supplies Mitoxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export. Customers receive product handling support and cold‑chain logistics to maintain stability.

What is Mitoxantrone used for?

Mitoxantrone is used in oncology to target rapidly proliferating malignant cells across several cancer types.

Acute myeloid leukemia: induces remission by disrupting DNA replication in leukemic blasts. Metastatic breast cancer: reduces tumor burden and delays disease progression. Prostate cancer: provides disease control in hormone‑refractory cases. Non‑Hodgkin lymphoma: contributes to response rates when combined with other chemotherapy agents.

What are the side effects of Mitoxantrone?

Mitoxantrone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Alopecia - Fatigue

Serious or Rare Side Effects: - Cardiac toxicity (dose‑related cardiomyopathy) - Secondary acute myeloid leukemia - Severe infections

What precautions apply to Mitoxantrone?

Mitoxantrone requires careful monitoring and specific safety measures before and during therapy.

Cardiac monitoring: baseline and periodic ejection‑fraction assessment. Hematologic monitoring: regular complete blood count to detect myelosuppression. Infection risk: avoid use in patients with active severe infections. Pregnancy and lactation: contraindicated unless benefits clearly outweigh risks. Contraception: advise effective contraception during treatment and for several months after therapy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantrone can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent anthracyclines: increased risk of cardiotoxicity. - Live vaccines: heightened risk of infection due to immunosuppression. - High‑dose radiation therapy: potential for enhanced tissue damage.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers: may change plasma concentrations. - Anticoagulants: possible increased bleeding tendency. - Nephrotoxic agents: additive renal toxicity risk.

Frequently asked questions

What is Mitoxan used for?+
Mitoxan (mitoxantrone) is an anthracenedone chemotherapy agent indicated for the treatment of acute myeloid leukemia, metastatic breast cancer, prostate cancer and non‑Hodgkin lymphoma. It is administered by intravenous infusion and works by damaging the DNA of rapidly dividing cancer cells.
How does mitoxantrone work?+
Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the enzyme from resealing DNA strands. This action creates double‑strand breaks, leading to apoptosis of malignant cells while sparing most normal, non‑dividing tissues.
What is the usual dose of Mitoxan?+
The dose of Mitoxan is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and cardiac function, and treatment protocol. No fixed regimen is provided here; the prescriber determines the appropriate dosing schedule.
Is Mitoxan safe in pregnancy or breastfeeding?+
Safety data for mitoxantrone in pregnancy and lactation are limited, and the drug is generally avoided because of potential fetal toxicity and unknown effects on breast‑fed infants. Use only if the potential benefit justifies the risk, and discuss alternatives with a specialist.
How do I order Mitoxan from GNH USA?+
To order Mitoxan, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.
How does Mitoxan compare with the main alternative drug or class?+
The primary alternative to mitoxantrone is the anthracycline class, such as doxorubicin. Both agents intercalate DNA, but mitoxantrone has a lower incidence of acute cardiotoxicity at equivalent doses, though cumulative cardiac risk remains. Choice depends on tumor type, prior exposure, and individual patient risk factors.
What are the storage and handling requirements for Mitoxan?+
Mitoxantrone for injection must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, use validated cold‑chain containers to maintain temperature stability.
How is Mitoxan administered?+
Mitoxan is supplied as a sterile solution for intravenous infusion. It is typically diluted in an appropriate carrier fluid and administered over a prescribed period, often ranging from 15 minutes to several hours, depending on the treatment protocol and patient tolerance.
What are the most serious risks to watch for while on Mitoxan?+
The most serious adverse risks include dose‑related cardiac toxicity (which may lead to irreversible cardiomyopathy), secondary acute myeloid leukemia, and severe infections due to profound myelosuppression. Regular cardiac monitoring, blood‑count checks, and infection surveillance are essential during therapy.
Who should not use Mitoxan?+
Mitoxan is contraindicated in patients with pre‑existing severe cardiac disease, uncontrolled infections, known hypersensitivity to mitoxantrone or its excipients, and in pregnant or breastfeeding women unless no safer alternative exists. Caution is also advised for individuals with significant hepatic or renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Medicamerc S.A
Origin
EU

Related products

Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU